All Preferred Holders Demand $52 Million Redemption Lifecore Cannot Yet Pay
Distressed
Company Background
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) based in Chaska, Minnesota, specializing in sterile injectable pharmaceuticals and hyaluronic acid manufacturing. It operates roughly 248,000 square feet of production and laboratory space and employs approximately 400 people. Revenue for the fiscal year ended May 25, 2025 was $128.9 million, and guidance for calendar year 2026 calls for $120-$125 million, reflecting a temporary step-down driven by a lost customer, excess HA inventory pre-built by its largest customer, and a delayed commercial launch.
The balance sheet is heavily encumbered. As of March 31, 2026, Lifecore carried $142.1 million in related-party debt — a term loan from Alcon Research, LLC maturing May 2029 — most of which accrues paid-in-kind interest, meaning the balance grows over time. Related-party interest expense alone was $6.9 million in Q1 2026. A $29.7 million derivative liability tied to that same facility sits alongside it. Total liabilities of $204.7 million exceed total assets of $225.5 million when the preferred stock is included as a mezzanine obligation, leaving stockholders in a deficit of $28.4 million as of March 31, 2026.
The operating business has been improving, however. Adjusted EBITDA for the seven-month transition period through December 31, 2025 was $13.1 million, up sharply from $2.6 million in the comparable prior period. Q1 2026 generated $4.7 million in operating cash flow, and the company signed three new commercial programs during the quarter. The capital structure, not the operating trajectory, is what now defines the company's near-term situation.
What Was Disclosed
Every holder of Lifecore's Series A Redeemable Convertible Preferred Stock submitted redemption notices between June 29 and June 30, 2026 — the first days on which redemption was permitted under the terms of the instrument. All 49,263 shares outstanding were tendered simultaneously, triggering a single, undivided cash obligation. The redemption price is $1,000 per share plus accrued and unpaid dividends; as of June 30, 2026, accrued dividends totaled $0.9 million and the total liquidation value was approximately $50.2 million. With dividends accruing on additional shares issued as paid-in-kind distributions, the total amount required to complete the redemption on December 28, 2026 — exactly 180 days from the notice date — is approximately $52.1 million. Any portion unpaid after that date accrues interest at 1% per month.